当前位置:首页 - 行情中心 - 康芝药业(300086) - 财务分析 - 现金流量表

康芝药业

(300086)

  

流通市值:29.44亿  总市值:30.40亿
流通股本:4.41亿   总股本:4.55亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金278,668,540.85122,821,964.09679,826,327.52467,153,549.82
  收到的税费返还65,352.0656,095.72151,328.22,600
  收到其他与经营活动有关的现金105,833,711.3982,124,678.273,331,971.5958,948,139.93
  经营活动现金流入小计384,567,604.3205,002,738.01753,309,627.31526,104,289.75
  购买商品、接受劳务支付的现金88,816,805.4250,624,762.09209,518,089.77137,396,619.35
  支付给职工以及为职工支付的现金41,553,881.9222,000,908.6284,840,184.0565,858,257.54
  支付的各项税费20,319,442.8712,619,721.6364,736,011.6350,360,391.48
  支付其他与经营活动有关的现金167,524,978.3379,244,207.7322,755,416.24267,193,737.17
  经营活动现金流出小计318,215,108.54164,489,600.04681,849,701.69520,809,005.54
  经营活动产生的现金流量净额66,352,495.7640,513,137.9771,459,925.625,295,284.21
二、投资活动产生的现金流量:
  处置固定资产、无形资产和其他长期资产收回的现金净额1,666.68-358,946.8358,946.8
  处置子公司及其他营业单位收到的现金净额--9,484,711.236,000,000
  投资活动现金流入的平衡项目0-00
  投资活动现金流入小计1,666.68-9,843,658.036,358,946.8
  购建固定资产、无形资产和其他长期资产支付的现金78,874,898.3673,881,504.4392,504,619.568,471,538.03
  投资支付的现金---200,000
  取得子公司及其他营业单位支付的现金--1,253,289.141,253,289.14
  投资活动现金流出小计78,874,898.3673,881,504.4393,757,908.6469,924,827.17
  投资活动产生的现金流量净额-78,873,231.68-73,881,504.43-83,914,250.61-63,565,880.37
三、筹资活动产生的现金流量:
  吸收投资收到的现金--15,936,918.2115,936,918.21
  取得借款收到的现金113,826,220.6860,503,915.74170,941,038.05121,441,038.05
  筹资活动现金流入小计113,826,220.6860,503,915.74186,877,956.26137,377,956.26
  偿还债务支付的现金158,385,492.543,000,000180,870,00084,560,000
  分配股利、利润或偿付利息支付的现金8,633,634.874,349,622.1219,872,395.6515,251,508.23
  支付其他与筹资活动有关的现金--200,000-
  筹资活动现金流出小计167,019,127.3747,349,622.12200,942,395.6599,811,508.23
  筹资活动产生的现金流量净额-53,192,906.6913,154,293.62-14,064,439.3937,566,448.03
四、汇率变动对现金及现金等价物的影响-13,875.16-3,171.4652,155.9248,785.35
五、现金及现金等价物净增加额-65,727,517.77-20,217,244.3-26,466,608.46-20,655,362.78
  加:期初现金及现金等价物余额113,185,485.94113,185,485.94134,643,932.86144,283,046.33
  期末现金及现金等价物余额47,457,968.1792,968,241.64108,177,324.4123,627,683.55
补充资料:
  净利润-55,108,349.75--224,426,506.01-
  资产减值准备4,763,014.85-60,301,809.97-
  固定资产和投资性房地产折旧29,189,001.11-53,825,442.43-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧29,189,001.11-53,825,442.43-
  无形资产摊销4,778,467.4-9,386,215.26-
  长期待摊费用摊销4,949,187.5-12,493,966.58-
  处置固定资产、无形资产和其他长期资产的损失455,864.28-228,016.41-
  公允价值变动损失--18,137,228.53-
  财务费用8,324,962.66-21,069,939.46-
  投资损失---16,688,228.22-
  递延所得税-5,505,377.35--7,566,192.36-
  其中:递延所得税资产减少-5,384,622.7--8,348,311.39-
    递延所得税负债增加-120,754.65-782,119.03-
  存货的减少-19,483,163.2-35,582,034.14-
  经营性应收项目的减少-17,180,162.37-92,703,251.47-
  经营性应付项目的增加110,686,032.03-15,849,426.58-
  现金的期末余额47,457,968.17-108,177,324.4-
  减:现金的期初余额113,185,485.94-134,643,932.86-
  现金及现金等价物的净增加额-65,727,517.77--26,466,608.46-
公告日期2025-08-282025-04-292025-04-292024-10-30
审计意见(境内)标准无保留意见
TOP↑